<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264147</url>
  </required_header>
  <id_info>
    <org_study_id>0663-086</org_study_id>
    <secondary_id>2005_077</secondary_id>
    <nct_id>NCT00264147</nct_id>
  </id_info>
  <brief_title>Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel-Group, 12-Week Study to Assess the Clinically Effective Dose Range of Etoricoxib and to Assess Its Safety and Tolerability in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To assess the clinically active dose range of study medication in the treatment of patients
      with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Who Met the ACR20 Responder Index Criteria</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of Patients Who Met the American College of Rheumatology Response Index (20%) Criteria (ACR20) (Based on the Time-Weighted Average Responses of the 12-Week Treatment I Period and Completed the Treatment I Period) (All Patients-Treated Population)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tender Joint Count (Out of 68 Joints) Time-Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment Period (All Patients-Treated Population)</measure>
    <time_frame>Time-weighted average change from baseline across Weeks 2, 7, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joint Count (Out of 66 Joints) Time-Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment Period (All Patients-Treated Population)</measure>
    <time_frame>Time-weighted average change from baseline across Weeks 2, 7, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Disease Activity (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)</measure>
    <time_frame>Time-weighted average change from baseline across Weeks 2, 7, and 12</time_frame>
    <description>0-mm indicates very well, 100-mm indicates very poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment of Disease Activity (0- to 4-Likert Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)</measure>
    <time_frame>Time-weighted average change from baseline across Weeks 2, 7, and 12</time_frame>
    <description>0 indicates very well, 4 indicates very poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Pain (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)</measure>
    <time_frame>Time-weighted average change from baseline across Weeks 2, 7, and 12</time_frame>
    <description>0-mm indicates very well, 100-mm indicates very poor.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">761</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Period I: 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etoricoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period I: 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etoricoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period I: 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etoricoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period I: 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etoricoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period I: 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period II: 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etoricoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period II: 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diclofenac</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib</intervention_name>
    <description>Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.</description>
    <arm_group_label>Period I: 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib</intervention_name>
    <description>Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.</description>
    <arm_group_label>Period I: 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib</intervention_name>
    <description>Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.</description>
    <arm_group_label>Period I: 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib</intervention_name>
    <description>Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.</description>
    <arm_group_label>Period I: 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo</intervention_name>
    <description>Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.</description>
    <arm_group_label>Period I: 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib</intervention_name>
    <description>Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.</description>
    <arm_group_label>Period II: 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: diclofenac</intervention_name>
    <description>Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.</description>
    <arm_group_label>Period II: 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with diagnosed rheumatoid arthritis (RA) for at least 6 months prior who is
             otherwise judged to be in general good health and who is currently taking nonsteroidal
             anti-inflammatory drugs (NSAIDS) to treat his/her RA symptoms

          -  Patient will need to stop taking these medications in order to participate, but can
             continue taking his/her other anti-rheumatic medications as long as they have been
             stable for certain periods of time

        Exclusion Criteria:

          -  Patients with a disease or medical condition(s) that could worsen or interfere with
             the evaluation of the effectiveness of study medication are not allowed to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Greenwald M, Peloso PM, Mandel D, Soto O, Mehta A, Frontera N, Boice JA, Zhan XJ, Curtis SP. Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis. Curr Med Res Opin. 2011 Oct;27(10):2033-42. doi: 10.1185/03007995.2011.614935. Epub 2011 Sep 12.</citation>
    <PMID>21905970</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2005</study_first_submitted>
  <study_first_submitted_qc>December 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2005</study_first_posted>
  <results_first_submitted>March 19, 2009</results_first_submitted>
  <results_first_submitted_qc>May 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2009</results_first_posted>
  <last_update_submitted>January 29, 2015</last_update_submitted>
  <last_update_submitted_qc>January 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arcoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>90 multicenter rheumatologists: US (71), Canada (14), Colombia (3), Switzerland (2), recruited 761 study patients from their patient pool and through advertising. First Patient In 04-Jan-2006, Last Patient Last Visit 26-Mar-2008.</recruitment_details>
      <pre_assignment_details>Patients must have taken Non Steroidal Anti-inflammatory Drugs (NSAIDs) at a therapeutic labeled dose on a regular basis and demonstrated a clinical response in the past and at screening. Following a protocol-specified &quot;washout,&quot; patients must have demonstrated disease activity and worsening in symptoms of Rheumatoid Arthritis from the screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Treatment I: Placebo orally once daily</description>
        </group>
        <group group_id="P2">
          <title>Etoricoxib 10 mg</title>
          <description>Treatment I: Etoricoxib 10 mg orally once daily</description>
        </group>
        <group group_id="P3">
          <title>Etoricoxib 30 mg</title>
          <description>Treatment I: Etoricoxib 30 mg orally once daily</description>
        </group>
        <group group_id="P4">
          <title>Etoricoxib 60 mg</title>
          <description>Treatment I: Etoricoxib 60 mg orally once daily</description>
        </group>
        <group group_id="P5">
          <title>Etoricoxib 90 mg</title>
          <description>Treatment I and II: Etoricoxib 90 mg orally once daily</description>
        </group>
        <group group_id="P6">
          <title>Diclofenac 150 mg (Treatment II)</title>
          <description>Treatment II: Diclofenac 75 mg orally twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment I Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="140"/>
                <participants group_id="P5" count="155"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63">Randomized to Treatment I period and remained on Treatment I period during course of study</participants>
                <participants group_id="P2" count="71">Randomized to Treatment I period and remained on Treatment I period during course of study</participants>
                <participants group_id="P3" count="74">Randomized to Treatment I period and remained on Treatment I period during course of study</participants>
                <participants group_id="P4" count="68">Randomized to Treatment I period and remained on Treatment I period during course of study</participants>
                <participants group_id="P5" count="99">Randomized to Treatment I period and remained on Treatment I period during course of study</participants>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient out of town for an extended time</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unblinded due to Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reassigned to Treatment II Period</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment II Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="180">Etoricoxib 10 mg (38), 30 mg (28), 60 mg (33), 90 mg (45) and placebo (36) reassigned to 90 mg (180)</participants>
                <participants group_id="P6" count="149">Etoricoxib 10 mg (34), 30 mg (37), 60 mg (29), and placebo (49) reassigned to diclofenac (149)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="147"/>
                <participants group_id="P6" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pre-scheduled total hip replacement</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Treatment I: Placebo orally once daily</description>
        </group>
        <group group_id="B2">
          <title>Etoricoxib 10 mg</title>
          <description>Treatment I: Etoricoxib 10 mg orally once daily</description>
        </group>
        <group group_id="B3">
          <title>Etoricoxib 30 mg</title>
          <description>Treatment I: Etoricoxib 30 mg orally once daily</description>
        </group>
        <group group_id="B4">
          <title>Etoricoxib 60 mg</title>
          <description>Treatment I: Etoricoxib 60 mg orally once daily</description>
        </group>
        <group group_id="B5">
          <title>Etoricoxib 90 mg</title>
          <description>Treatment I: Etoricoxib 90 mg orally once daily</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="161"/>
            <count group_id="B2" value="154"/>
            <count group_id="B3" value="151"/>
            <count group_id="B4" value="140"/>
            <count group_id="B5" value="155"/>
            <count group_id="B6" value="761"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="11.80"/>
                    <measurement group_id="B2" value="58.7" spread="11.92"/>
                    <measurement group_id="B3" value="56.2" spread="11.17"/>
                    <measurement group_id="B4" value="57.7" spread="10.96"/>
                    <measurement group_id="B5" value="54.9" spread="12.54"/>
                    <measurement group_id="B6" value="57.0" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B5" value="122"/>
                    <measurement group_id="B6" value="613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Rheumatism Association Functional Class</title>
          <description>Class I: Completely able to perform usual activities of daily living (self care, vocational, and avocational), Class II: Able to perform usual self-care and vocational activities, but limited in avocational activities, Class III: Able to perform usual self-care activities, but limited in vocational and avocational activities</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="98"/>
                    <measurement group_id="B6" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corticosteroid User</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="106"/>
                    <measurement group_id="B6" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Modifying Antirheumatic Drug User</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="131"/>
                    <measurement group_id="B6" value="629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Modifying Antirheumatic Drug or Corticosteroid User</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="136"/>
                    <measurement group_id="B6" value="654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Methotrexate User</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="93"/>
                    <measurement group_id="B6" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="62"/>
                    <measurement group_id="B6" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="112"/>
                    <measurement group_id="B6" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rheumatoid Factor</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="121"/>
                    <measurement group_id="B6" value="599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-User</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-User</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="93"/>
                    <measurement group_id="B6" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.42" spread="16.54"/>
                    <measurement group_id="B2" value="76.12" spread="18.48"/>
                    <measurement group_id="B3" value="77.36" spread="20.00"/>
                    <measurement group_id="B4" value="75.72" spread="19.54"/>
                    <measurement group_id="B5" value="77.97" spread="18.61"/>
                    <measurement group_id="B6" value="76.73" spread="18.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Rheumatoid Arthritis (Years)</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.0" spread="9.78"/>
                    <measurement group_id="B2" value="10.1" spread="9.76"/>
                    <measurement group_id="B3" value="11.2" spread="8.40"/>
                    <measurement group_id="B4" value="10.3" spread="10.18"/>
                    <measurement group_id="B5" value="9.9" spread="9.98"/>
                    <measurement group_id="B6" value="10.3" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161.93" spread="9.71"/>
                    <measurement group_id="B2" value="163.63" spread="8.55"/>
                    <measurement group_id="B3" value="164.57" spread="9.13"/>
                    <measurement group_id="B4" value="162.96" spread="9.22"/>
                    <measurement group_id="B5" value="163.49" spread="10.04"/>
                    <measurement group_id="B6" value="163.30" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator Global Assessment of Disease Activity (0 to 4 - Likert Scale)</title>
          <description>(0 to 4 - Likert Scale) 0=Very Well, 1=Well, 2=Fair, 3=Poor, 4=Very Poor</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.71" spread="0.61"/>
                    <measurement group_id="B2" value="2.71" spread="0.67"/>
                    <measurement group_id="B3" value="2.75" spread="0.66"/>
                    <measurement group_id="B4" value="2.69" spread="0.63"/>
                    <measurement group_id="B5" value="2.73" spread="0.65"/>
                    <measurement group_id="B6" value="2.72" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Global Assessment of Disease Activity (0-To- 100 Millimeter Visual Analog Scale)</title>
          <description>(0- to 100-mm Visual Analog Scale) 0 mm= No pain, 100 mm= Extreme pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.08" spread="18.67"/>
                    <measurement group_id="B2" value="69.28" spread="19.37"/>
                    <measurement group_id="B3" value="66.56" spread="20.47"/>
                    <measurement group_id="B4" value="66.60" spread="19.58"/>
                    <measurement group_id="B5" value="65.42" spread="18.45"/>
                    <measurement group_id="B6" value="66.79" spread="19.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Global Assessment of Pain (0- To- 100-mm Visual Analog Scale)</title>
          <description>(0- to 100-mm Visual Analog Scale) 0 mm= No pain, 100 mm= Extreme pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.66" spread="16.03"/>
                    <measurement group_id="B2" value="72.42" spread="17.32"/>
                    <measurement group_id="B3" value="70.95" spread="16.67"/>
                    <measurement group_id="B4" value="69.54" spread="18.24"/>
                    <measurement group_id="B5" value="71.08" spread="17.55"/>
                    <measurement group_id="B6" value="71.38" spread="17.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count (Out of 66 Joints)</title>
          <units>Number of Swollen Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.05" spread="9.79"/>
                    <measurement group_id="B2" value="17.75" spread="10.86"/>
                    <measurement group_id="B3" value="16.74" spread="10.11"/>
                    <measurement group_id="B4" value="15.79" spread="9.40"/>
                    <measurement group_id="B5" value="16.30" spread="10.05"/>
                    <measurement group_id="B6" value="16.53" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count (Out of 68 Joints)</title>
          <units>Number of Tender Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.91" spread="14.17"/>
                    <measurement group_id="B2" value="28.33" spread="15.42"/>
                    <measurement group_id="B3" value="27.19" spread="14.97"/>
                    <measurement group_id="B4" value="26.76" spread="14.37"/>
                    <measurement group_id="B5" value="27.25" spread="16.11"/>
                    <measurement group_id="B6" value="27.30" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Who Met the ACR20 Responder Index Criteria</title>
        <description>Proportion of Patients Who Met the American College of Rheumatology Response Index (20%) Criteria (ACR20) (Based on the Time-Weighted Average Responses of the 12-Week Treatment I Period and Completed the Treatment I Period) (All Patients-Treated Population)</description>
        <time_frame>12 weeks</time_frame>
        <population>All-Patients-Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment I: Placebo orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 10 mg</title>
            <description>Treatment I: Etoricoxib 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Etoricoxib 30 mg</title>
            <description>Treatment I: Etoricoxib 30 mg orally once daily</description>
          </group>
          <group group_id="O4">
            <title>Etoricoxib 60 mg</title>
            <description>Treatment I: Etoricoxib 60 mg orally once daily</description>
          </group>
          <group group_id="O5">
            <title>Etoricoxib 90 mg</title>
            <description>Treatment I: Etoricoxib 90 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Met the ACR20 Responder Index Criteria</title>
          <description>Proportion of Patients Who Met the American College of Rheumatology Response Index (20%) Criteria (ACR20) (Based on the Time-Weighted Average Responses of the 12-Week Treatment I Period and Completed the Treatment I Period) (All Patients-Treated Population)</description>
          <population>All-Patients-Treated Population</population>
          <units>Proportion of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="140"/>
                <count group_id="O5" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.57"/>
                    <measurement group_id="O2" value="35.06"/>
                    <measurement group_id="O3" value="37.75"/>
                    <measurement group_id="O4" value="38.57"/>
                    <measurement group_id="O5" value="47.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>Cochran-Armitage trend test</method>
            <method_desc>A step-down procedure and Abelson-Tukey scaling were used for the trend test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>Cochran-Armitage trend test</method>
            <method_desc>A step-down procedure and Abelson-Tukey scaling were used for the trend test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in percentage of patients</param_type>
            <param_value>18.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.84</ci_lower_limit>
            <ci_upper_limit>28.65</ci_upper_limit>
            <estimate_desc>CI based on the Wilson's score method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in percentage of patients</param_type>
            <param_value>10.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>20.46</ci_upper_limit>
            <estimate_desc>CI based on the Wilson's score method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in percentage of patients</param_type>
            <param_value>9.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.25</ci_lower_limit>
            <ci_upper_limit>19.39</ci_upper_limit>
            <estimate_desc>CI based on the Wilson's score method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>difference in percentage of patients</param_type>
            <param_value>6.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.76</ci_lower_limit>
            <ci_upper_limit>16.61</ci_upper_limit>
            <estimate_desc>CI based on the Wilson's score method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tender Joint Count (Out of 68 Joints) Time-Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment Period (All Patients-Treated Population)</title>
        <time_frame>Time-weighted average change from baseline across Weeks 2, 7, and 12</time_frame>
        <population>All-Patients-Treatment Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment I: Placebo orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 10 mg</title>
            <description>Treatment I: Etoricoxib 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Etoricoxib 30 mg</title>
            <description>Treatment I: Etoricoxib 30 mg orally once daily</description>
          </group>
          <group group_id="O4">
            <title>Etoricoxib 60 mg</title>
            <description>Treatment I: Etoricoxib 60 mg orally once daily</description>
          </group>
          <group group_id="O5">
            <title>Etoricoxib 90 mg</title>
            <description>Treatment I: Etoricoxib 90 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Tender Joint Count (Out of 68 Joints) Time-Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment Period (All Patients-Treated Population)</title>
          <population>All-Patients-Treatment Population</population>
          <units>Tender Joint Count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="138"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.13" spread="9.55"/>
                    <measurement group_id="O2" value="-11.01" spread="13.07"/>
                    <measurement group_id="O3" value="-10.96" spread="11.00"/>
                    <measurement group_id="O4" value="-9.56" spread="11.85"/>
                    <measurement group_id="O5" value="-12.06" spread="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.221</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.44</ci_lower_limit>
            <ci_upper_limit>-1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.91</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.13</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.88</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swollen Joint Count (Out of 66 Joints) Time-Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment Period (All Patients-Treated Population)</title>
        <time_frame>Time-weighted average change from baseline across Weeks 2, 7, and 12</time_frame>
        <population>All-Patients-Treatment Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment I: Placebo orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 10 mg</title>
            <description>Treatment I: Etoricoxib 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Etoricoxib 30 mg</title>
            <description>Treatment I: Etoricoxib 30 mg orally once daily</description>
          </group>
          <group group_id="O4">
            <title>Etoricoxib 60 mg</title>
            <description>Treatment I: Etoricoxib 60 mg orally once daily</description>
          </group>
          <group group_id="O5">
            <title>Etoricoxib 90 mg</title>
            <description>Treatment I: Etoricoxib 90 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Swollen Joint Count (Out of 66 Joints) Time-Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment Period (All Patients-Treated Population)</title>
          <population>All-Patients-Treatment Population</population>
          <units>Swollen Joint Count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="138"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.39" spread="7.34"/>
                    <measurement group_id="O2" value="-6.58" spread="8.11"/>
                    <measurement group_id="O3" value="-6.91" spread="7.27"/>
                    <measurement group_id="O4" value="-6.25" spread="7.48"/>
                    <measurement group_id="O5" value="-7.77" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.64</ci_lower_limit>
            <ci_upper_limit>-0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.44</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.63</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.89</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment of Disease Activity (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)</title>
        <description>0-mm indicates very well, 100-mm indicates very poor.</description>
        <time_frame>Time-weighted average change from baseline across Weeks 2, 7, and 12</time_frame>
        <population>All Patients-Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment I: Placebo orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 10 mg</title>
            <description>Treatment I: Etoricoxib 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Etoricoxib 30 mg</title>
            <description>Treatment I: Etoricoxib 30 mg orally once daily</description>
          </group>
          <group group_id="O4">
            <title>Etoricoxib 60 mg</title>
            <description>Treatment I: Etoricoxib 60 mg orally once daily</description>
          </group>
          <group group_id="O5">
            <title>Etoricoxib 90 mg</title>
            <description>Treatment I: Etoricoxib 90 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment of Disease Activity (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)</title>
          <description>0-mm indicates very well, 100-mm indicates very poor.</description>
          <population>All Patients-Treated Population</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="134"/>
                <count group_id="O5" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.32" spread="25.66"/>
                    <measurement group_id="O2" value="-19.90" spread="23.61"/>
                    <measurement group_id="O3" value="-21.12" spread="24.47"/>
                    <measurement group_id="O4" value="-21.49" spread="26.71"/>
                    <measurement group_id="O5" value="-25.75" spread="25.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.38</ci_lower_limit>
            <ci_upper_limit>-8.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.52</ci_lower_limit>
            <ci_upper_limit>-3.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.11</ci_lower_limit>
            <ci_upper_limit>-3.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.27</ci_lower_limit>
            <ci_upper_limit>-0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Assessment of Disease Activity (0- to 4-Likert Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)</title>
        <description>0 indicates very well, 4 indicates very poor.</description>
        <time_frame>Time-weighted average change from baseline across Weeks 2, 7, and 12</time_frame>
        <population>All-Patients-Treatment Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment I: Placebo orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 10 mg</title>
            <description>Treatment I: Etoricoxib 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Etoricoxib 30 mg</title>
            <description>Treatment I: Etoricoxib 30 mg orally once daily</description>
          </group>
          <group group_id="O4">
            <title>Etoricoxib 60 mg</title>
            <description>Treatment I: Etoricoxib 60 mg orally once daily</description>
          </group>
          <group group_id="O5">
            <title>Etoricoxib 90 mg</title>
            <description>Treatment I: Etoricoxib 90 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment of Disease Activity (0- to 4-Likert Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)</title>
          <description>0 indicates very well, 4 indicates very poor.</description>
          <population>All-Patients-Treatment Population</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="138"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="1.06"/>
                    <measurement group_id="O2" value="-0.93" spread="0.94"/>
                    <measurement group_id="O3" value="-1.09" spread="1.01"/>
                    <measurement group_id="O4" value="-1.01" spread="0.94"/>
                    <measurement group_id="O5" value="-1.24" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment of Pain (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)</title>
        <description>0-mm indicates very well, 100-mm indicates very poor.</description>
        <time_frame>Time-weighted average change from baseline across Weeks 2, 7, and 12</time_frame>
        <population>All-Patients-Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment I: Placebo orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 10 mg</title>
            <description>Treatment I: Etoricoxib 10 mg orally once daily</description>
          </group>
          <group group_id="O3">
            <title>Etoricoxib 30 mg</title>
            <description>Treatment I: Etoricoxib 30 mg orally once daily</description>
          </group>
          <group group_id="O4">
            <title>Etoricoxib 60 mg</title>
            <description>Treatment I: Etoricoxib 60 mg orally once daily</description>
          </group>
          <group group_id="O5">
            <title>Etoricoxib 90 mg</title>
            <description>Treatment I: Etoricoxib 90 mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment of Pain (0- to 100-mm Visual Analog Scale) Time Weighted Average Change From Baseline (Flare/Randomization Visit) in the 12-Week Treatment I Period (All Patients-Treated Population)</title>
          <description>0-mm indicates very well, 100-mm indicates very poor.</description>
          <population>All-Patients-Treated Population</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="137"/>
                <count group_id="O5" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.44" spread="23.42"/>
                    <measurement group_id="O2" value="-21.95" spread="22.87"/>
                    <measurement group_id="O3" value="-22.75" spread="23.86"/>
                    <measurement group_id="O4" value="-22.25" spread="26.58"/>
                    <measurement group_id="O5" value="-31.07" spread="24.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <p_value_desc>Overall alpha=0.05 for multiple comparisons with a step-down procedure (p-values subsequent to the first non-significant p-value were not reported).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on a trend test with a step-down procedure and Abelson-Tukey scaling.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.62</ci_lower_limit>
            <ci_upper_limit>-9.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.52</ci_lower_limit>
            <ci_upper_limit>-0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.53</ci_lower_limit>
            <ci_upper_limit>-1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.81</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Treatment I Period</title>
          <description>Treatment I: Placebo orally once daily</description>
        </group>
        <group group_id="E2">
          <title>Etoricoxib 10 mg Treatment I Period</title>
          <description>Treatment I: Etoricoxib 10 mg orally once daily</description>
        </group>
        <group group_id="E3">
          <title>Etoricoxib 30 mg Treatment I Period</title>
          <description>Treatment I: Etoricoxib 30 mg orally once daily</description>
        </group>
        <group group_id="E4">
          <title>Etoricoxib 60 mg Treatment I Period</title>
          <description>Treatment I: Etoricoxib 60 mg orally once daily</description>
        </group>
        <group group_id="E5">
          <title>Etoricoxib 90 mg Treatment I Period</title>
          <description>Treatment I: Etoricoxib 90 mg orally once daily</description>
        </group>
        <group group_id="E6">
          <title>Etoricoxib 90 mg Treatment II Period</title>
          <description>Treatment II: Etoricoxib 90 mg orally once daily</description>
        </group>
        <group group_id="E7">
          <title>Diclofenac 150 mg Treatment II Period</title>
          <description>Treatment II: Diclofenac 75 mg orally twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="4"/>
                <counts group_id="E4" subjects_affected="1"/>
                <counts group_id="E5" subjects_affected="5"/>
                <counts group_id="E6" subjects_affected="3"/>
                <counts group_id="E7" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ileus Paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dislocation Of Joint Prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Heat Exhaustion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant Melanoma In Situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Obsessive-Compulsive Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28"/>
                <counts group_id="E2" subjects_affected="19"/>
                <counts group_id="E3" subjects_affected="29"/>
                <counts group_id="E4" subjects_affected="37"/>
                <counts group_id="E5" subjects_affected="39"/>
                <counts group_id="E6" subjects_affected="25"/>
                <counts group_id="E7" subjects_affected="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

